Clinical Trial Update: Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing darolutamide and enzalutamide in castration-resistant prostate cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Bayer | Conditions: Prostatic Cancer, Castration-Resistant | Phase 2 | Status: TERMINATED | Results posted: 2023-08-04